首页 > 最新文献

Research and Reports in Urology最新文献

英文 中文
A Triplicated Bladder with Diphallia; Rare Variant of Duplicate Exstrophy. 具有双生殖器的三联膀胱;重复外植体的罕见变种。
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2023-01-01 DOI: 10.2147/RRU.S397296
Hana Abebe Gebreselassie, Binyam Gebremedihin Godu, Hiwote Girma Assefa, Maru Gama Erge

Background: Exstrophy variants are well described urologic anomalies. They are characterized by atypical anatomical and physical findings than those found in patients with classic bladder exstrophy and epispadias malformation. The combination of these anomalies with duplicated phallus is a rare occurrence. Here we present a neonate with a rare form of exstrophy variant associated with penile duplication.

Case summary: One day old male neonate who was born at term was admitted to our neonatal intensive care unit. He had lower abdominal wall defect and open bladder plate with no visible ureteric orifices. There were two completely separate phalluses with penopubic epispadias and urethral orifices draining urine. Both testes were descended. Abdominopelvic ultrasound showed normal upper urinary tract. He was prepared and operated with intra operative finding of complete bladder duplication in the sagittal plane and each bladder has its own ureter. The open bladder plate which had no connection with both ureters and urethras was excised. The pubic symphysis was approximated without osteotomy and abdominal wall was closed. He was immobilized with mummy wrap. He had uneventful post-operative course and was discharged on the 7th post-operative day. He was evaluated on the 3rd month post operatively and he was thriving well with no complications.

Conclusion: The occurrence of a triplicated bladder along with diphallia is an exceptionally rare urologic anomaly. As a number of variations are possible in this spectrum, the management of neonates with this anomaly should be individualized.

背景:外翻变异是一种描述良好的泌尿系统异常。与典型的膀胱外翻和上膈畸形患者相比,其解剖和物理表现不典型。这些异常与重复阴茎的结合是罕见的。在这里,我们提出了一个新生儿与阴茎复制相关的一种罕见形式的外型变异。病例总结:1天大的男婴足月出生,住进我们的新生儿重症监护室。他有下腹壁缺损和开放膀胱板,没有可见输尿管口。有两个完全独立的阴茎,阴茎上有阴茎和尿道口排出尿液。两个睾丸都降下来了。腹部盆腔超声示上尿路正常。他准备和手术术中发现完全膀胱重复在矢状面,每个膀胱有自己的输尿管。切除与输尿管和尿道均无连接的开放膀胱板。逼近耻骨联合,不截骨,封闭腹壁。他被木乃伊包裹住了。术后过程平稳,于术后第7天出院。术后第3个月对患者进行评估,患者健康状况良好,无并发症。结论:三膀胱伴白喉是一种极为罕见的泌尿系统异常。由于在这一谱系中可能有许多变化,因此对这种异常的新生儿的管理应该个体化。
{"title":"A Triplicated Bladder with Diphallia; Rare Variant of Duplicate Exstrophy.","authors":"Hana Abebe Gebreselassie,&nbsp;Binyam Gebremedihin Godu,&nbsp;Hiwote Girma Assefa,&nbsp;Maru Gama Erge","doi":"10.2147/RRU.S397296","DOIUrl":"https://doi.org/10.2147/RRU.S397296","url":null,"abstract":"<p><strong>Background: </strong>Exstrophy variants are well described urologic anomalies. They are characterized by atypical anatomical and physical findings than those found in patients with classic bladder exstrophy and epispadias malformation. The combination of these anomalies with duplicated phallus is a rare occurrence. Here we present a neonate with a rare form of exstrophy variant associated with penile duplication.</p><p><strong>Case summary: </strong>One day old male neonate who was born at term was admitted to our neonatal intensive care unit. He had lower abdominal wall defect and open bladder plate with no visible ureteric orifices. There were two completely separate phalluses with penopubic epispadias and urethral orifices draining urine. Both testes were descended. Abdominopelvic ultrasound showed normal upper urinary tract. He was prepared and operated with intra operative finding of complete bladder duplication in the sagittal plane and each bladder has its own ureter. The open bladder plate which had no connection with both ureters and urethras was excised. The pubic symphysis was approximated without osteotomy and abdominal wall was closed. He was immobilized with mummy wrap. He had uneventful post-operative course and was discharged on the 7th post-operative day. He was evaluated on the 3rd month post operatively and he was thriving well with no complications.</p><p><strong>Conclusion: </strong>The occurrence of a triplicated bladder along with diphallia is an exceptionally rare urologic anomaly. As a number of variations are possible in this spectrum, the management of neonates with this anomaly should be individualized.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"15 ","pages":"109-112"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/91/rru-15-109.PMC9990448.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9078997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maintaining Serum Hemoglobin Levels Within the Physiological Range Prevented Bladder Tamponade Recurrence Due to Radiation-Induced Hemorrhagic Cystitis: A Case Report. 维持血清血红蛋白水平在生理范围内可预防放射性出血性膀胱炎所致膀胱填塞复发1例报告。
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2023-01-01 DOI: 10.2147/RRU.S420329
Norichika Ueda, Mototaka Sato, Atsuki Matsukawa, Yuta Oki, Ryoya Mizuno, Mai Akiyama, Norihide Tei, Osamu Miyake

Radiation-induced hemorrhagic cystitis is a refractory disease that can cause severe hematuria and bladder tamponade. Bladder tamponade due to radiation-induced hemorrhagic cystitis can often recur repeatedly and markedly reduce the quality of life. However, no blood test parameter has been studied yet regarding the prevention of bladder tamponade recurrence. An 84-year-old patient with a history of radiation therapy for cervical cancer was repeatedly hospitalized for bladder tamponade due to radiation-induced hemorrhagic cystitis. At each hospitalization, blood transfusions were performed to treat severe anemia as the first treatment, resulting in hematuria improvement, and the patient was discharged without invasive treatments such as transurethral coagulation. However, anemia developed gradually after each discharge. The anemia progression was obviously unrelated to macrohematuria because macrohematuria did not appear during that period. When the serum hemoglobin level decreased below the physiological range, bladder tamponade recurred. Based on these findings, we posited that the monitoring of the serum hemoglobin level could be useful to predict the occurrence of bladder tamponade. We hypothesized that if the serum hemoglobin level did not fall below the physiological range, bladder tamponade would not occur. We treated chronic anemia after determining its cause and kept serum hemoglobin levels within the physiological range. Since the treatment was initiated, bladder tamponade has not recurred in over 27 months. In this case, the monitoring of the serum hemoglobin level was useful to predict the occurrence of bladder tamponade due to radiation-induced hemorrhagic cystitis. By maintaining serum hemoglobin levels within the physiological range, we successfully prevented the recurrence of bladder tamponade due to radiation-induced hemorrhagic cystitis.

放射性出血性膀胱炎是一种难治性疾病,可引起严重血尿和膀胱填塞。放射性出血性膀胱炎引起的膀胱填塞可反复发作,显著降低患者的生活质量。然而,目前还没有关于预防膀胱填塞复发的血液检测参数的研究。84岁宫颈癌放射治疗史患者因放射引起出血性膀胱炎膀胱填塞多次住院。每次住院均以输血治疗重度贫血为第一治疗方法,血尿改善,出院时未进行经尿道凝血等侵入性治疗。然而,每次出院后,贫血逐渐发展。贫血的进展显然与大血尿无关,因为在此期间没有出现大血尿。当血清血红蛋白水平低于生理范围时,膀胱填塞复发。基于这些发现,我们假设监测血清血红蛋白水平可能有助于预测膀胱填塞的发生。我们假设,如果血清血红蛋白水平不低于生理范围,就不会发生膀胱填塞。我们在确定病因后对慢性贫血进行治疗,并将血清血红蛋白水平控制在生理范围内。自开始治疗以来,膀胱填塞已超过27个月未复发。在这种情况下,监测血清血红蛋白水平有助于预测由于辐射引起的出血性膀胱炎引起的膀胱填塞的发生。通过将血清血红蛋白水平维持在生理范围内,我们成功地防止了辐射引起的出血性膀胱炎引起的膀胱填塞的复发。
{"title":"Maintaining Serum Hemoglobin Levels Within the Physiological Range Prevented Bladder Tamponade Recurrence Due to Radiation-Induced Hemorrhagic Cystitis: A Case Report.","authors":"Norichika Ueda,&nbsp;Mototaka Sato,&nbsp;Atsuki Matsukawa,&nbsp;Yuta Oki,&nbsp;Ryoya Mizuno,&nbsp;Mai Akiyama,&nbsp;Norihide Tei,&nbsp;Osamu Miyake","doi":"10.2147/RRU.S420329","DOIUrl":"https://doi.org/10.2147/RRU.S420329","url":null,"abstract":"<p><p>Radiation-induced hemorrhagic cystitis is a refractory disease that can cause severe hematuria and bladder tamponade. Bladder tamponade due to radiation-induced hemorrhagic cystitis can often recur repeatedly and markedly reduce the quality of life. However, no blood test parameter has been studied yet regarding the prevention of bladder tamponade recurrence. An 84-year-old patient with a history of radiation therapy for cervical cancer was repeatedly hospitalized for bladder tamponade due to radiation-induced hemorrhagic cystitis. At each hospitalization, blood transfusions were performed to treat severe anemia as the first treatment, resulting in hematuria improvement, and the patient was discharged without invasive treatments such as transurethral coagulation. However, anemia developed gradually after each discharge. The anemia progression was obviously unrelated to macrohematuria because macrohematuria did not appear during that period. When the serum hemoglobin level decreased below the physiological range, bladder tamponade recurred. Based on these findings, we posited that the monitoring of the serum hemoglobin level could be useful to predict the occurrence of bladder tamponade. We hypothesized that if the serum hemoglobin level did not fall below the physiological range, bladder tamponade would not occur. We treated chronic anemia after determining its cause and kept serum hemoglobin levels within the physiological range. Since the treatment was initiated, bladder tamponade has not recurred in over 27 months. In this case, the monitoring of the serum hemoglobin level was useful to predict the occurrence of bladder tamponade due to radiation-induced hemorrhagic cystitis. By maintaining serum hemoglobin levels within the physiological range, we successfully prevented the recurrence of bladder tamponade due to radiation-induced hemorrhagic cystitis.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"15 ","pages":"395-401"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/e7/rru-15-395.PMC10455857.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10112704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical Management of Male Stress Incontinence: Techniques, Indications, and Pearls for Success. 男性压力性尿失禁的外科治疗:技术、适应症和成功的秘诀。
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2023-01-01 DOI: 10.2147/RRU.S395359
Wesley J Smith, Maia E VanDyke, Nikit Venishetty, Brian T Langford, Bryce P Franzen, Allen F Morey

Purpose: Male stress urinary incontinence (SUI) has detrimental and long-lasting effects on patients. Management of this condition is an evolving field with multiple options for surgical treatment. We sought to review the pre-operative evaluation, intra-operative considerations, post-operative care, and future directions for treatment of male SUI.

Methods: A literature review was performed using the PubMed platform to identify peer-reviewed, English-language articles published within the last 5 years pertaining to management of male stress urinary incontinence with an emphasis on devices currently on the market in the United States including the artificial urinary sphincter (AUS), male urethral slings, and the ProACTTM system. Patient selection criteria, success rates, and complications were compared between the studies.

Results: Twenty articles were included in the final contemporary review. Pre-operative workup most commonly included demonstration of incontinence, PPD, and cystoscopy. Definition of success varied by study; the most common definition used was social continence (0-1 pads per day). Reported rates of success were higher for the AUS than for male urethral slings (73-93% vs 70-90%, respectively). Complications for these procedures include urinary retention, erosions, infections, and device malfunction. Newer treatment options including adjustable balloon systems and adjustable slings show promise but lack long-term follow-up.

Conclusion: Patient selection remains the primary consideration for surgical decision-making for management of male SUI. The AUS continues to be the gold standard for moderate-to-severe male SUI but comes with inherent risk of need for revision. Male slings may be a superior option for appropriately selected men with mild incontinence but are inferior to the AUS for moderate and severe incontinence. Ongoing research will shed light on long-term results for newer options such as the ProACT and REMEEX systems.

目的:男性压力性尿失禁(SUI)对患者的影响是有害且持久的。这种情况的管理是一个不断发展的领域,有多种选择的手术治疗。我们试图回顾术前评估、术中注意事项、术后护理和男性SUI治疗的未来方向。方法:使用PubMed平台进行文献综述,以识别最近5年内发表的同行评议的关于男性压力性尿失禁管理的英文文章,重点是目前在美国市场上的设备,包括人工尿括约肌(AUS)、男性尿道吊带和ProACTTM系统。比较两项研究的患者选择标准、成功率和并发症。结果:20篇文章被纳入最终的当代综述。术前检查通常包括尿失禁、PPD和膀胱镜检查。成功的定义因学习而异;最常用的定义是社交自制(每天0-1块)。据报道,AUS的成功率高于男性尿道吊带(分别为73-93%和70-90%)。这些手术的并发症包括尿潴留、腐蚀、感染和设备故障。较新的治疗方案,包括可调节气囊系统和可调节吊带显示出希望,但缺乏长期随访。结论:患者选择仍然是男性SUI手术决策的首要考虑因素。AUS仍然是中度至重度男性SUI的黄金标准,但存在需要修订的固有风险。对于轻度尿失禁的男性,男性吊带可能是一个更好的选择,但对于中度和重度尿失禁,它不如AUS。正在进行的研究将揭示新的选择,如ProACT和REMEEX系统的长期结果。
{"title":"Surgical Management of Male Stress Incontinence: Techniques, Indications, and Pearls for Success.","authors":"Wesley J Smith,&nbsp;Maia E VanDyke,&nbsp;Nikit Venishetty,&nbsp;Brian T Langford,&nbsp;Bryce P Franzen,&nbsp;Allen F Morey","doi":"10.2147/RRU.S395359","DOIUrl":"https://doi.org/10.2147/RRU.S395359","url":null,"abstract":"<p><strong>Purpose: </strong>Male stress urinary incontinence (SUI) has detrimental and long-lasting effects on patients. Management of this condition is an evolving field with multiple options for surgical treatment. We sought to review the pre-operative evaluation, intra-operative considerations, post-operative care, and future directions for treatment of male SUI.</p><p><strong>Methods: </strong>A literature review was performed using the PubMed platform to identify peer-reviewed, English-language articles published within the last 5 years pertaining to management of male stress urinary incontinence with an emphasis on devices currently on the market in the United States including the artificial urinary sphincter (AUS), male urethral slings, and the ProACT<sup>TM</sup> system. Patient selection criteria, success rates, and complications were compared between the studies.</p><p><strong>Results: </strong>Twenty articles were included in the final contemporary review. Pre-operative workup most commonly included demonstration of incontinence, PPD, and cystoscopy. Definition of success varied by study; the most common definition used was social continence (0-1 pads per day). Reported rates of success were higher for the AUS than for male urethral slings (73-93% vs 70-90%, respectively). Complications for these procedures include urinary retention, erosions, infections, and device malfunction. Newer treatment options including adjustable balloon systems and adjustable slings show promise but lack long-term follow-up.</p><p><strong>Conclusion: </strong>Patient selection remains the primary consideration for surgical decision-making for management of male SUI. The AUS continues to be the gold standard for moderate-to-severe male SUI but comes with inherent risk of need for revision. Male slings may be a superior option for appropriately selected men with mild incontinence but are inferior to the AUS for moderate and severe incontinence. Ongoing research will shed light on long-term results for newer options such as the ProACT and REMEEX systems.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"15 ","pages":"217-232"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/a0/rru-15-217.PMC10290851.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9716109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Arabic Information on YouTube About Erectile Dysfunction Based on Scientific Evidence? YouTube上关于勃起功能障碍的阿拉伯语信息有科学依据吗?
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2023-01-01 DOI: 10.2147/RRU.S410127
Meshari A Alzahrani, Muhammad Anwar Khan, Basel O Hakami, Abdulaziz Alahmadi, Mohammed Alzahrani, Faisal Alsaleh, Muath Almurayyi, Omar Safar, Mohammad Shakil Ahmad

Background: Online medical education is critical for public health literacy and physician efficacy, but it must be trustworthy. Although it has the potential to be a useful resource for medical education, users must be able to identify reliable content.

Objective: To assess the scientific quality of Arabic-language video content related to erectile dysfunction that is available on YouTube to learn what information our patients can handle online.

Materials and methods: A comprehensive search of the YouTube database was carried out to identify videos related to erectile dysfunction published in Arabic. The search was conducted using the following keywords: "Erectile dysfunction", "Sexual dysfunction" and "Impotence". Without a time, limit, the search was carried out until January 1, 2023. The quality assessment of the videos was done using the Kappa score.

Results: The videos in our sample had up to one million views (average 2,627,485.6), and the kappa index was 0.86 (p <0.001). Of these videos, 16% were considered scientific evidence-based (SEB), and 84% were considered not scientific evidence-based (NSEB) (p <0.001). The NSEB group addressed details concerning natural remedies, the Psychosocial sphere, and lifestyle, whereas the SEB group tended to be more concerned with physiopathology, etiology, endothelial dysfunction, diagnosis, psychosocial treatment, oral treatment, injections, or prosthesis.

Conclusion: On social media, misleading or incorrect information about erectile dysfunction is widely disseminated. This research may support urological and technical oversight and emphasizes guiding patients to the best men's health options.

背景:在线医学教育对公共卫生素养和医生效能至关重要,但它必须值得信赖。虽然它有可能成为医学教育的有用资源,但用户必须能够识别可靠的内容。目的:评估YouTube上与勃起功能障碍相关的阿拉伯语视频内容的科学质量,以了解我们的患者可以在线处理哪些信息。材料和方法:对YouTube数据库进行全面搜索,以确定阿拉伯语出版的与勃起功能障碍相关的视频。搜索使用以下关键词:“勃起功能障碍”、“性功能障碍”和“阳痿”。搜寻工作没有时间限制,一直进行到2023年1月1日。视频的质量评估是用Kappa评分完成的。结果:我们样本中的视频浏览量高达100万次(平均2,627,485.6),kappa指数为0.86 (p)。结论:在社交媒体上,关于勃起功能障碍的误导或错误信息广泛传播。这项研究可能支持泌尿学和技术监督,并强调指导患者做出最佳的男性健康选择。
{"title":"Is Arabic Information on YouTube About Erectile Dysfunction Based on Scientific Evidence?","authors":"Meshari A Alzahrani,&nbsp;Muhammad Anwar Khan,&nbsp;Basel O Hakami,&nbsp;Abdulaziz Alahmadi,&nbsp;Mohammed Alzahrani,&nbsp;Faisal Alsaleh,&nbsp;Muath Almurayyi,&nbsp;Omar Safar,&nbsp;Mohammad Shakil Ahmad","doi":"10.2147/RRU.S410127","DOIUrl":"https://doi.org/10.2147/RRU.S410127","url":null,"abstract":"<p><strong>Background: </strong>Online medical education is critical for public health literacy and physician efficacy, but it must be trustworthy. Although it has the potential to be a useful resource for medical education, users must be able to identify reliable content.</p><p><strong>Objective: </strong>To assess the scientific quality of Arabic-language video content related to erectile dysfunction that is available on YouTube to learn what information our patients can handle online.</p><p><strong>Materials and methods: </strong>A comprehensive search of the YouTube database was carried out to identify videos related to erectile dysfunction published in Arabic. The search was conducted using the following keywords: \"Erectile dysfunction\", \"Sexual dysfunction\" and \"Impotence\". Without a time, limit, the search was carried out until January 1, 2023. The quality assessment of the videos was done using the Kappa score.</p><p><strong>Results: </strong>The videos in our sample had up to one million views (average 2,627,485.6), and the kappa index was 0.86 (p <0.001). Of these videos, 16% were considered scientific evidence-based (SEB), and 84% were considered not scientific evidence-based (NSEB) (p <0.001). The NSEB group addressed details concerning natural remedies, the Psychosocial sphere, and lifestyle, whereas the SEB group tended to be more concerned with physiopathology, etiology, endothelial dysfunction, diagnosis, psychosocial treatment, oral treatment, injections, or prosthesis.</p><p><strong>Conclusion: </strong>On social media, misleading or incorrect information about erectile dysfunction is widely disseminated. This research may support urological and technical oversight and emphasizes guiding patients to the best men's health options.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"15 ","pages":"261-272"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/4c/rru-15-261.PMC10314774.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. 癌症耐Castion-Ristant前列腺患者的治疗前景:患者选择和未满足的临床需求。
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-09-29 eCollection Date: 2022-01-01 DOI: 10.2147/RRU.S360444
Fabio Turco, Silke Gillessen, Richard Cathomas, Consuelo Buttigliero, Ursula Maria Vogl

Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease. However, in recent years, several treatments have been shown to improve the outcome of CRPC patients both in the non-metastatic (nmCRPC) as well as the metastatic setting (mCRPC). In nmCRPC patients with a PSA doubling time <10 months, the addition of enzalutamide, apalutamide and darolutamide to androgen deprivation therapy (ADT) compared to ADT alone resulted in improved metastases free (MFS) and overall survival (OS). For mCRPC patients, several treatment options have been shown to be effective: two taxane based chemotherapies (docetaxel and cabazitaxel), two androgen-receptor pathway inhibitors (ARPI) (abiraterone and enzalutamide), two radiopharmaceutical agents (radium 223 and 177Lutetium-PSMA-617), one immunotherapy treatment (sipuleucel-T) and two poly ADP-ribose polymerase (PARP) inhibitors (olaparib and rucaparib). Pembrolizumab is US Food and Drug Administration (FDA) approved in all MSI high solid tumors, although a very small proportion of prostate cancer patients harboring this characteristic will benefit. Despite having a broad variety of treatments available, there are still several unmet clinical needs for CRPC. The objective of this review was to describe the therapeutic landscape in CRPC patients, to identify criteria for selecting patients for specific treatments currently available, and to address the current challenges in this setting.

转移性去势耐受性癌症(CRPC)是一种不可避免的致命疾病。然而,近年来,几种治疗方法已被证明在非转移性(nmCRPC)和转移性(mCRPC)中都能改善CRPC患者的预后。PSA加倍时间的nmCRPC患者
{"title":"Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs.","authors":"Fabio Turco,&nbsp;Silke Gillessen,&nbsp;Richard Cathomas,&nbsp;Consuelo Buttigliero,&nbsp;Ursula Maria Vogl","doi":"10.2147/RRU.S360444","DOIUrl":"10.2147/RRU.S360444","url":null,"abstract":"<p><p>Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease. However, in recent years, several treatments have been shown to improve the outcome of CRPC patients both in the non-metastatic (nmCRPC) as well as the metastatic setting (mCRPC). In nmCRPC patients with a PSA doubling time <10 months, the addition of enzalutamide, apalutamide and darolutamide to androgen deprivation therapy (ADT) compared to ADT alone resulted in improved metastases free (MFS) and overall survival (OS). For mCRPC patients, several treatment options have been shown to be effective: two taxane based chemotherapies (docetaxel and cabazitaxel), two androgen-receptor pathway inhibitors (ARPI) (abiraterone and enzalutamide), two radiopharmaceutical agents (radium 223 and 177Lutetium-PSMA-617), one immunotherapy treatment (sipuleucel-T) and two poly ADP-ribose polymerase (PARP) inhibitors (olaparib and rucaparib). Pembrolizumab is US Food and Drug Administration (FDA) approved in all MSI high solid tumors, although a very small proportion of prostate cancer patients harboring this characteristic will benefit. Despite having a broad variety of treatments available, there are still several unmet clinical needs for CRPC. The objective of this review was to describe the therapeutic landscape in CRPC patients, to identify criteria for selecting patients for specific treatments currently available, and to address the current challenges in this setting.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 ","pages":"339-350"},"PeriodicalIF":1.6,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/71/rru-14-339.PMC9529226.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10273869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats 给药荆芥籽提取物改善雄性Wistar大鼠睾丸激素诱导的良性前列腺增生(BPH)
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-05-01 DOI: 10.2147/RRU.S365598
Shan Sasidharan, Srinivasakumar Kp, A. Bhaumik, Sreemoy Kanti Das, Hareebndran Nair J
Introduction Benign prostatic hyperplasia (BPH) is a major chronic disease affecting men, and the therapeutic agents currently used to manage it have significant side effects. As a result, an alternative medicine with improved therapeutic properties with no side effects is desperately needed. The current investigation aims to study whether the Caesalpinia bonduc seed extracts (ethanolic-A, hydroalcoholic-B, and aqueous-C) have inhibitory potential on testosterone propionate (TP)-induced BPH in Wistar rats. Methods Wistar rats (male) were randomly allocated to one of five groups: control, BPH (TP-3 mg/kg, subcutaneously daily), low dose (TP + C. bonduc seed extracts – 200 mg/kg body weight), high dose (TP + C. bonduc seed extracts – 400 mg/kg body weight), and standard drug (TP + finasteride – 10 mg/kg body weight). At the end of drug treatment, the rats were sacrificed and their serum and prostates were taken for biochemical and histological studies. Results C. bonduc seed extracts treatment significantly decreased prostate weight and prostatic index in rats with TP-induced BPH. The seed extracts exhibited a potent inhibitory effect on dihydrotestosterone (DHT) in serum and prostate. In addition, the PSA level in the serum showed a noteworthy decrease in comparison with the BPH group. Histopathological examination also indicated that extracts improved the tissue morphology of the prostate significantly. Out of three extracts tested, ethanolic and hydroalcoholic extract recorded significant effect. Finally, liquid chromatography quadrupole time-of-flight mass spectrometry (LC/MS-QTOF) analysis showed that the major compounds present in the extracts were tocopherols, fucosterol, linoleic acid, β-amyrin, β-sitosterol, campesterol, cassane furanoditerpene, norcassane furanoditerpene and other diterpenes. Conclusion Thus, C. bonduc seed extracts could be a potential source for the formulation of new drug for managing BPH. To the best of our knowledge, this is the first scientific animal investigation into the use of C. bonduc seed extract for the management of BPH.
引言良性前列腺增生(BPH)是一种影响男性的主要慢性疾病,目前用于治疗它的药物有显著的副作用。因此,迫切需要一种具有改善治疗性能且无副作用的替代药物。本研究的目的是研究金合欢种子提取物(乙醇-A、乙醇-B和水-C)是否对丙酸睾酮(TP)诱导的Wistar大鼠前列腺增生具有抑制作用。方法Wistar大鼠(雄性)随机分为五组:对照组、前列腺增生组(TP-3 mg/kg,每天皮下注射)、低剂量组(TP+C.bonduc种子提取物–200 mg/kg体重)、高剂量组(TP+C.bonduk种子提取物–400 mg/kg体重)和标准药物组(TP+非那雄胺–10 mg/kg体重)。药物治疗结束时,处死大鼠,取其血清和前列腺进行生化和组织学研究。结果邦杜克种子提取物治疗能显著降低TP诱导的BPH大鼠前列腺重量和前列腺指数。种子提取物对血清和前列腺中的二氢睾酮(DHT)具有强大的抑制作用。此外,与前列腺增生组相比,血清中的PSA水平显著下降。组织病理学检查还表明,提取物显著改善了前列腺的组织形态。在测试的三种提取物中,乙醇和水醇提取物的效果显著。最后,液相色谱-四极杆飞行时间质谱(LC/MS-QTOF)分析表明,提取物中存在的主要化合物为生育酚、岩藻甾醇、亚油酸、β-胰淀素、β-谷甾醇、樟脑酯醇、呋喃二萜、norcassane呋喃二萜和其他二萜。结论邦杜克种子提取物是研制治疗前列腺增生新药的潜在来源。据我们所知,这是首次对邦杜克C.bonduc种子提取物用于BPH治疗的科学动物调查。
{"title":"Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats","authors":"Shan Sasidharan, Srinivasakumar Kp, A. Bhaumik, Sreemoy Kanti Das, Hareebndran Nair J","doi":"10.2147/RRU.S365598","DOIUrl":"https://doi.org/10.2147/RRU.S365598","url":null,"abstract":"Introduction Benign prostatic hyperplasia (BPH) is a major chronic disease affecting men, and the therapeutic agents currently used to manage it have significant side effects. As a result, an alternative medicine with improved therapeutic properties with no side effects is desperately needed. The current investigation aims to study whether the Caesalpinia bonduc seed extracts (ethanolic-A, hydroalcoholic-B, and aqueous-C) have inhibitory potential on testosterone propionate (TP)-induced BPH in Wistar rats. Methods Wistar rats (male) were randomly allocated to one of five groups: control, BPH (TP-3 mg/kg, subcutaneously daily), low dose (TP + C. bonduc seed extracts – 200 mg/kg body weight), high dose (TP + C. bonduc seed extracts – 400 mg/kg body weight), and standard drug (TP + finasteride – 10 mg/kg body weight). At the end of drug treatment, the rats were sacrificed and their serum and prostates were taken for biochemical and histological studies. Results C. bonduc seed extracts treatment significantly decreased prostate weight and prostatic index in rats with TP-induced BPH. The seed extracts exhibited a potent inhibitory effect on dihydrotestosterone (DHT) in serum and prostate. In addition, the PSA level in the serum showed a noteworthy decrease in comparison with the BPH group. Histopathological examination also indicated that extracts improved the tissue morphology of the prostate significantly. Out of three extracts tested, ethanolic and hydroalcoholic extract recorded significant effect. Finally, liquid chromatography quadrupole time-of-flight mass spectrometry (LC/MS-QTOF) analysis showed that the major compounds present in the extracts were tocopherols, fucosterol, linoleic acid, β-amyrin, β-sitosterol, campesterol, cassane furanoditerpene, norcassane furanoditerpene and other diterpenes. Conclusion Thus, C. bonduc seed extracts could be a potential source for the formulation of new drug for managing BPH. To the best of our knowledge, this is the first scientific animal investigation into the use of C. bonduc seed extract for the management of BPH.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"225 - 239"},"PeriodicalIF":1.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42050087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A Drug-Coated Balloon Treatment for Urethral Stricture Disease: Three-Year Results from the ROBUST I Study 尿道狭窄疾病的药物包被球囊治疗:鲁棒I研究的三年结果
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-05-01 DOI: 10.2147/RRU.S359872
R. Virasoro, J. DeLong, R. Estrella, M. Pichardo, R. Rodriguez Lay, G. Espino, S. Elliott
Introduction Endoscopic management of male anterior urethral stricture disease is common; however, repeat treatment is associated with high recurrence rates. Here, we report the 3-year results of the ROBUST I trial, which evaluated the safety and efficacy of the Optilume® drug coated balloon (DCB) in men with recurrent urethral strictures. Methods Adult men with recurrent bulbar urethral strictures ≤2 cm in length and 1–4 prior endoscopic interventions were treated with the Optilume DCB. Functional success was defined as ≥50% reduction in International Prostate Symptom Score (IPSS) without need for retreatment. Other outcomes included quality of life, maximum flow rate, post-void residual urine volume, erectile function, and freedom from repeat intervention. Results Of the 53 enrolled and treated men, 33 completed the 3-year visit, with 10 patients experiencing clinical failures at previous visits, giving a total of 43 subjects evaluable for the functional success endpoint. Functional success was achieved in 67% (29/43) and freedom from retreatment in 77% (33/43). Average IPSS improved from 25.2 at baseline to 5.5 at 3 years (p<0.0001). Significant improvements were observed in quality of life, flow rate, and post-void residual urine volume. Erectile function was not affected by treatment. Device-related adverse events were mild or moderate in nature and resolved quickly after onset. There were no serious treatment-related adverse events. Conclusion Symptomatic improvement after treatment with the Optilume DCB was maintained through 3 years in a population highly susceptible to recurrent urethral stricture disease. This minimally invasive therapy is safe with no negative impact on sexual function.
男性前尿道狭窄的内镜治疗是常见的;然而,重复治疗与高复发率相关。在此,我们报告了ROBUST I试验的3年结果,该试验评估了Optilume®药物涂层球囊(DCB)治疗复发性尿道狭窄男性的安全性和有效性。方法采用Optilume DCB治疗长度≤2cm的复发性球根性尿道狭窄成年男性,并进行1-4次内窥镜介入治疗。功能性成功定义为国际前列腺症状评分(IPSS)降低≥50%,无需再治疗。其他结果包括生活质量、最大流速、排尿后残余尿量、勃起功能和免于重复干预。结果在53名入选和接受治疗的男性中,33人完成了3年的访视,其中10名患者在之前的访视中出现了临床失败,共有43名受试者可评估功能成功终点。67%(29/43)获得功能性成功,77%(33/43)免于再治疗。平均IPSS从基线时的25.2改善到3年时的5.5(p<0.0001)。在生活质量、流速和排尿后残余尿量方面观察到显著改善。治疗未影响勃起功能。器械相关不良事件性质为轻度或中度,发病后迅速缓解。没有严重的治疗相关不良事件。结论Optilume DCB治疗复发性尿道狭窄患者后,症状改善持续3年。这种微创治疗是安全的,对性功能没有负面影响。
{"title":"A Drug-Coated Balloon Treatment for Urethral Stricture Disease: Three-Year Results from the ROBUST I Study","authors":"R. Virasoro, J. DeLong, R. Estrella, M. Pichardo, R. Rodriguez Lay, G. Espino, S. Elliott","doi":"10.2147/RRU.S359872","DOIUrl":"https://doi.org/10.2147/RRU.S359872","url":null,"abstract":"Introduction Endoscopic management of male anterior urethral stricture disease is common; however, repeat treatment is associated with high recurrence rates. Here, we report the 3-year results of the ROBUST I trial, which evaluated the safety and efficacy of the Optilume® drug coated balloon (DCB) in men with recurrent urethral strictures. Methods Adult men with recurrent bulbar urethral strictures ≤2 cm in length and 1–4 prior endoscopic interventions were treated with the Optilume DCB. Functional success was defined as ≥50% reduction in International Prostate Symptom Score (IPSS) without need for retreatment. Other outcomes included quality of life, maximum flow rate, post-void residual urine volume, erectile function, and freedom from repeat intervention. Results Of the 53 enrolled and treated men, 33 completed the 3-year visit, with 10 patients experiencing clinical failures at previous visits, giving a total of 43 subjects evaluable for the functional success endpoint. Functional success was achieved in 67% (29/43) and freedom from retreatment in 77% (33/43). Average IPSS improved from 25.2 at baseline to 5.5 at 3 years (p<0.0001). Significant improvements were observed in quality of life, flow rate, and post-void residual urine volume. Erectile function was not affected by treatment. Device-related adverse events were mild or moderate in nature and resolved quickly after onset. There were no serious treatment-related adverse events. Conclusion Symptomatic improvement after treatment with the Optilume DCB was maintained through 3 years in a population highly susceptible to recurrent urethral stricture disease. This minimally invasive therapy is safe with no negative impact on sexual function.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"177 - 183"},"PeriodicalIF":1.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43157637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality 一种新的基于三基因特征的风险评分(P评分),用于估计前列腺癌特异性死亡率的风险
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-05-01 DOI: 10.2147/RRU.S358169
F. Söderdahl, Lidi Xu, J. Bring, M. Häggman
Purpose To develop and validate a risk score (P-score) algorithm which includes previously described three-gene signature and clinicopathological parameters to predict the risk of death from prostate cancer (PCa) in a retrospective cohort. Patients and Methods A total of 591 PCa patients diagnosed between 2003 and 2008 in Stockholm, Sweden, with a median clinical follow-up time of 7.6 years (1–11 years) were included in this study. Expression of a three-gene signature (IGFBP3, F3, VGLL3) was measured in formalin-fixed paraffin-embedded material from diagnostic core needle biopsies (CNB) of these patients. A point-based scoring system based on a Fine-Gray competing risk model was used to establish the P-score based on the three-gene signature combined with PSA value, Gleason score and tumor stage at diagnosis. The endpoint was PCa-specific mortality, while other causes of death were treated as a competing risk. Out of the 591 patients, 315 patients (estimation cohort) were selected to develop the P-score. The P-score was subsequently validated in an independent validation cohort of 276 patients. Results The P-score was established ranging from the integers 0 to 15. Each one-unit increase was associated with a hazard ratio of 1.39 (95% confidence interval: 1.27–1.51, p < 0.001). The P-score was validated and performed better in predicting PCa-specific mortality than both D’Amico (0.76 vs 0.70) and NCCN (0.76 vs 0.71) by using the concordance index for competing risk. Similar improvement patterns are shown by time-dependent area under the curve. As demonstrated by cumulative incidence function, both P-score and gene signature stratified PCa patients into significantly different risk groups. Conclusion We developed the P-score, a risk stratification system for newly diagnosed PCa patients by integrating a three-gene signature measured in CNB tissue. The P-score could provide valuable decision support to distinguish PCa patients with favorable and unfavorable outcomes and hence improve treatment decisions.
目的:在回顾性队列中,开发并验证一种风险评分(P-score)算法,该算法包括先前描述的三基因特征和临床病理参数,以预测前列腺癌(PCa)的死亡风险。患者和方法本研究共纳入2003 - 2008年在瑞典斯德哥尔摩诊断的591例PCa患者,临床随访时间中位数为7.6年(1-11年)。在这些患者的诊断芯针活检(CNB)中检测福尔马林固定石蜡包埋材料中三个基因特征(IGFBP3, F3, VGLL3)的表达。采用基于Fine-Gray竞争风险模型的积分评分系统,结合PSA值、Gleason评分和诊断时肿瘤分期,建立基于三基因特征的p评分。终点是前列腺癌特异性死亡率,而其他死亡原因被视为竞争风险。在591例患者中,选择315例患者(估计队列)进行p评分。随后在276例患者的独立验证队列中验证了p评分。结果建立的p评分范围为0 ~ 15。每增加一个单位,风险比为1.39(95%可信区间:1.27-1.51,p < 0.001)。通过竞争风险的一致性指数,p -评分在预测前列腺癌特异性死亡率方面优于D 'Amico (0.76 vs 0.70)和NCCN (0.76 vs 0.71)。曲线下随时间变化的面积显示了类似的改进模式。累积发生率函数表明,P-score和基因标记将PCa患者分层为明显不同的风险组。我们通过整合CNB组织中测量的三个基因标记,开发了新诊断的PCa患者的风险分层系统P-score。p -评分可以提供有价值的决策支持,以区分前列腺癌患者的有利和不利的结果,从而改善治疗决策。
{"title":"A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality","authors":"F. Söderdahl, Lidi Xu, J. Bring, M. Häggman","doi":"10.2147/RRU.S358169","DOIUrl":"https://doi.org/10.2147/RRU.S358169","url":null,"abstract":"Purpose To develop and validate a risk score (P-score) algorithm which includes previously described three-gene signature and clinicopathological parameters to predict the risk of death from prostate cancer (PCa) in a retrospective cohort. Patients and Methods A total of 591 PCa patients diagnosed between 2003 and 2008 in Stockholm, Sweden, with a median clinical follow-up time of 7.6 years (1–11 years) were included in this study. Expression of a three-gene signature (IGFBP3, F3, VGLL3) was measured in formalin-fixed paraffin-embedded material from diagnostic core needle biopsies (CNB) of these patients. A point-based scoring system based on a Fine-Gray competing risk model was used to establish the P-score based on the three-gene signature combined with PSA value, Gleason score and tumor stage at diagnosis. The endpoint was PCa-specific mortality, while other causes of death were treated as a competing risk. Out of the 591 patients, 315 patients (estimation cohort) were selected to develop the P-score. The P-score was subsequently validated in an independent validation cohort of 276 patients. Results The P-score was established ranging from the integers 0 to 15. Each one-unit increase was associated with a hazard ratio of 1.39 (95% confidence interval: 1.27–1.51, p < 0.001). The P-score was validated and performed better in predicting PCa-specific mortality than both D’Amico (0.76 vs 0.70) and NCCN (0.76 vs 0.71) by using the concordance index for competing risk. Similar improvement patterns are shown by time-dependent area under the curve. As demonstrated by cumulative incidence function, both P-score and gene signature stratified PCa patients into significantly different risk groups. Conclusion We developed the P-score, a risk stratification system for newly diagnosed PCa patients by integrating a three-gene signature measured in CNB tissue. The P-score could provide valuable decision support to distinguish PCa patients with favorable and unfavorable outcomes and hence improve treatment decisions.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"203 - 217"},"PeriodicalIF":1.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43563202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Use of Temporary Membrane-Covered Self-Expandable Metallic Stent – UVENTATM for Treatment of Recurrent Bulbar Urethral Stricture 临时膜覆盖自扩张金属支架UVENTATM治疗复发性球尿道狭窄
IF 1.6 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-05-01 DOI: 10.2147/RRU.S363557
Ibrahim Alnadhari, Nabil N. Moohialdin, V. Sampige, O. Ali, Osama Abdeljaleel, M. Salah, O. Sedigh, A. Shamsodini, A. Al-Ansari
Introduction Recurrent urethral stricture is a real challenge. Interestingly use of temporary double layered self-expanding nitinol urethral stent with polytetrafluoroethylene (PTFE) membrane coating (UventaTM, Taewoong Medical, South Korea) has been recently reported with promising short-term results in recurrent urethral stricture. However most of the reported studies are published as abstracts of either case reports or case series of miniscule numbers. The aim of our study is to evaluate the outcome of this temporary urethral stent in patients with recurrent urethral stricture after urethroplasty as well as after multiple visual internal urethrotomy. Materials and Methods In this retrospective study, 22 patients had placement of double-layered self-expanding stent with PTFE membrane coating (Uventa, Taewoong Medical) for recurrent bulbar strictures. The present study included cases between 2017 and 2020. The stricture in each patient were evaluated with Uroflowmetry and ascending urethrography. The data of demographic and clinical characteristics included age, aetiology, location and length of stricture, along with maximum urinary flow rate (Qmax), number of previous interventions, and stent-related complications. Results The overall clinical success was achieved in 13/22 (59.1%) of patients at a median follow-up of 17 months (range 2–44). The mean maximum urine flow rates were 7.07 ± 3.55mL/sec, 23.50 ± 10.41mL/sec, 21.41± 15.55 mL/sec, 14.88 ± 9.77 and 17.63 ± 12.28 mL/sec before, while stent in place, at 3 months, 6 months and 12 months after the procedure, respectively. Conclusion In our study, the success rate of temporary urethral stent placement has remained at 59.1% at a median follow-up of 17 months. We conclude that further randomized controlled studies with long-term follow up are required to fully evaluate the outcome.
引言复发性尿道狭窄是一个真正的挑战。有趣的是,最近有报道称,使用具有聚四氟乙烯(PTFE)膜涂层的临时双层自膨胀镍钛诺尿道支架(UventaTM,Taewoong Medical,South Korea)治疗复发性尿道狭窄具有良好的短期效果。然而,大多数报道的研究都是以病例报告或微小数字病例系列的摘要形式发表的。我们研究的目的是评估这种临时尿道支架在尿道成形术后和多次尿道内切开术后复发性尿道狭窄患者中的效果。材料和方法在这项回顾性研究中,22名患者因复发性延髓狭窄而放置了双层PTFE膜自膨胀支架(Uventa,Taewoong Medical)。本研究包括2017年至2020年间的病例。每例患者的狭窄情况均采用尿流量测定法和上行尿道造影术进行评估。人口统计学和临床特征的数据包括年龄、病因、狭窄的位置和长度,以及最大尿流量(Qmax)、既往干预次数和支架相关并发症。结果在中位随访17个月(2-4 4个月)时,13/22(59.1%)的患者获得了总体临床成功。支架置入前、术后3个月、6个月和12个月的平均最大尿流量分别为7.07±3.55mL/s、23.50±10.41mL/s、21.41±15.55mL/s、14.88±9.77和17.63±12.28mL/s。结论在我们的研究中,在中位随访17个月时,临时尿道支架置入的成功率保持在59.1%。我们的结论是,需要进一步的随机对照研究和长期随访来全面评估结果。
{"title":"Use of Temporary Membrane-Covered Self-Expandable Metallic Stent – UVENTATM for Treatment of Recurrent Bulbar Urethral Stricture","authors":"Ibrahim Alnadhari, Nabil N. Moohialdin, V. Sampige, O. Ali, Osama Abdeljaleel, M. Salah, O. Sedigh, A. Shamsodini, A. Al-Ansari","doi":"10.2147/RRU.S363557","DOIUrl":"https://doi.org/10.2147/RRU.S363557","url":null,"abstract":"Introduction Recurrent urethral stricture is a real challenge. Interestingly use of temporary double layered self-expanding nitinol urethral stent with polytetrafluoroethylene (PTFE) membrane coating (UventaTM, Taewoong Medical, South Korea) has been recently reported with promising short-term results in recurrent urethral stricture. However most of the reported studies are published as abstracts of either case reports or case series of miniscule numbers. The aim of our study is to evaluate the outcome of this temporary urethral stent in patients with recurrent urethral stricture after urethroplasty as well as after multiple visual internal urethrotomy. Materials and Methods In this retrospective study, 22 patients had placement of double-layered self-expanding stent with PTFE membrane coating (Uventa, Taewoong Medical) for recurrent bulbar strictures. The present study included cases between 2017 and 2020. The stricture in each patient were evaluated with Uroflowmetry and ascending urethrography. The data of demographic and clinical characteristics included age, aetiology, location and length of stricture, along with maximum urinary flow rate (Qmax), number of previous interventions, and stent-related complications. Results The overall clinical success was achieved in 13/22 (59.1%) of patients at a median follow-up of 17 months (range 2–44). The mean maximum urine flow rates were 7.07 ± 3.55mL/sec, 23.50 ± 10.41mL/sec, 21.41± 15.55 mL/sec, 14.88 ± 9.77 and 17.63 ± 12.28 mL/sec before, while stent in place, at 3 months, 6 months and 12 months after the procedure, respectively. Conclusion In our study, the success rate of temporary urethral stent placement has remained at 59.1% at a median follow-up of 17 months. We conclude that further randomized controlled studies with long-term follow up are required to fully evaluate the outcome.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"219 - 223"},"PeriodicalIF":1.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42058315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Imaging and Chemical Analysis of External and Internal Ureteral Stent Encrustation. 输尿管内外支架包膜的影像学和化学分析
IF 2 Q2 UROLOGY & NEPHROLOGY Pub Date : 2022-04-23 eCollection Date: 2022-01-01 DOI: 10.2147/RRU.S364336
Tal Amitay-Rosen, Ishai Dror, Yaniv Shilo, Brian Berkowitz

Introduction: Ureteral stents are effective in alleviating flow disruptions in the urinary tract, whether due to ureteral stones, strictures or extrinsic ureteral obstruction. However, significant stent encrustation on the external and/or internal stent lumen walls can occur, which may interfere with stent functioning and/or removal. Currently, there is only limited, generally qualitative, information on the distribution, mineral structure, and chemical content of these deposits, particularly in terms of stent lumen encrustation.

Objective: To quantify, in an initial investigation, external and internal encrustation in representative, intact ureteral stents. The study investigates possible correlations between patterns of external and internal encrustation, determines mineral structure and chemical composition, and examines the potential for stent lumen obstruction even in the absence of external stent wall encrustation.

Study design: High-resolution, laboratory micro-computed tomography (micro-CT) was used to non-destructively image external and internal stent encrustation in four representative stents. X-ray diffractometry (XRD) and scanning electron microscopy-energy dispersive x-ray spectroscopy (SEM-EDS) enabled parallel analysis of mineral structure and chemical content of samples collected from external and internal encrusted material along the distal, proximal and mid-ureteral stent regions.

Results: Extensive stent lumen encrustation can occur within any region of a stent, with only incidental or minor external encrustation, along the entire length of the stent. External and internal encrusted materials in a given stent are generally similar, consisting of a combination of amorphous (mostly organic) and crystalline mineral deposits.

Conclusion: Micro-CT demonstrates that significant stent lumen encrustation can occur, which can lead to partial or full stent lumen occlusion, even when the exterior stent wall is essentially free of encrusted material.

引言输尿管支架可有效缓解因输尿管结石、狭窄或外源性输尿管梗阻引起的尿路血流中断。然而,支架管腔外壁和/或内壁上可能会出现明显的支架结垢,这可能会干扰支架的功能和/或移除。目前,关于这些沉积物的分布、矿物结构和化学含量,特别是支架管腔结垢的信息有限,通常是定性的。目的在初步研究中,量化具有代表性的完整输尿管支架的内外部结垢。该研究调查了外部和内部结垢模式之间的可能相关性,确定了矿物结构和化学成分,并检查了即使在没有外部支架壁结垢的情况下支架管腔阻塞的可能性。研究设计高分辨率实验室微型计算机断层扫描(micro-CT)用于对四种具有代表性的支架的内外部支架结垢进行无损成像。X射线衍射仪(XRD)和扫描电子显微镜-能量色散X射线光谱法(SEM-EDS)能够并行分析从输尿管支架远端、近端和中段的外部和内部包裹材料中收集的样品的矿物结构和化学含量。结果在支架的任何区域都可能发生广泛的支架管腔结垢,在支架的整个长度上只有偶然或轻微的外部结垢。给定支架中的外部和内部包覆材料通常相似,由非晶(主要是有机)和结晶矿物沉积物的组合组成。结论显微CT显示,即使支架外壁基本上没有结垢物质,也会发生明显的支架管腔结垢,从而导致部分或全部支架管腔堵塞。
{"title":"Imaging and Chemical Analysis of External and Internal Ureteral Stent Encrustation.","authors":"Tal Amitay-Rosen, Ishai Dror, Yaniv Shilo, Brian Berkowitz","doi":"10.2147/RRU.S364336","DOIUrl":"10.2147/RRU.S364336","url":null,"abstract":"<p><strong>Introduction: </strong>Ureteral stents are effective in alleviating flow disruptions in the urinary tract, whether due to ureteral stones, strictures or extrinsic ureteral obstruction. However, significant stent encrustation on the external and/or internal stent lumen walls can occur, which may interfere with stent functioning and/or removal. Currently, there is only limited, generally qualitative, information on the distribution, mineral structure, and chemical content of these deposits, particularly in terms of stent lumen encrustation.</p><p><strong>Objective: </strong>To quantify, in an initial investigation, external and internal encrustation in representative, intact ureteral stents. The study investigates possible correlations between patterns of external and internal encrustation, determines mineral structure and chemical composition, and examines the potential for stent lumen obstruction even in the absence of external stent wall encrustation.</p><p><strong>Study design: </strong>High-resolution, laboratory micro-computed tomography (micro-CT) was used to non-destructively image external and internal stent encrustation in four representative stents. X-ray diffractometry (XRD) and scanning electron microscopy-energy dispersive x-ray spectroscopy (SEM-EDS) enabled parallel analysis of mineral structure and chemical content of samples collected from external and internal encrusted material along the distal, proximal and mid-ureteral stent regions.</p><p><strong>Results: </strong>Extensive stent lumen encrustation can occur within any region of a stent, with only incidental or minor external encrustation, along the entire length of the stent. External and internal encrusted materials in a given stent are generally similar, consisting of a combination of amorphous (mostly organic) and crystalline mineral deposits.</p><p><strong>Conclusion: </strong>Micro-CT demonstrates that significant stent lumen encrustation can occur, which can lead to partial or full stent lumen occlusion, even when the exterior stent wall is essentially free of encrusted material.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"14 1","pages":"159-166"},"PeriodicalIF":2.0,"publicationDate":"2022-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49442592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Research and Reports in Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1